Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles

Open Access

Original Research

Med Arch. 2012; 66(1): 41-44

Influence of the Prostate Volume, Prostate Specific Antigen Density and Number of Biopsy Samples on Prostate Cancer Detection

Damir Aganovic, Alden Prcic, Benjamin Kulovac, Osman Hadziosmanovic.

Cited by (2)

Aim: Establish the main differences in the prostate volume, prostate specific antigen density (PSAD), number of biopsy samples in patients with primarily or rebiopsy detected prostate cancer. Materials and methods: In the 2007-2009 period, at the KCUS Urology Clinic, there were 379 TRUS guided prostate biopsies in 323 patients with known prostate volume. The total of 56 patients (17.3%) underwent the first rebiopsy, primarily due to precancerous lesions. The mean prostate volume, ranges of prostate size, PSAT, PSAD and the number of biopsy samples were analysed retrospectively, and the main characteristics in patients with primarily and rebiopsy diagnosed Pca were evaluated as well. Results: The first biopsy cancer detection rate was 29.6% (112/379). The rebiopsy detection rate was 30.3%. There was no statistically significant difference in the prostate volume and the number of biopsy samples among the total number of patients with prostate cancer against the group with benign (suspected) findings. There was a higher Pca detection rate in patients with the prostate volume 60 cm3. PSAD was significantly higher in patients with PCa (0.24 vs. 0.18; p=0.013). The total of 27.2% of the patients with negative biopsy findings and 48% of the patients with diagnosed Pca had PSAD >0.15. PSAD showed sensitivity and specificity in prostate cancer detection of 50% and 75%, with PPV of 48%. Furthermore, the patients with PSAD >0.15 had a higher Gleason score versus the patients with PSAD

Key words: PCa, prostate biopsy, prostate volume, PSAD.

Similar Articles

Construction of a sensitive and selective plasmonic biosensor for prostate specific antigen by combining magnetic molecularly-imprinted polymer and surface-enhanced Raman spectroscopy.
Turan E, Zengin A, Suludere Z, Kalkan NĂ–, Tamer U
Talanta. 2022; 237(): 122926

Interrater agreement of contouring of the neurovascular bundles and internal pudendal arteries in neurovascular-sparing magnetic resonance-guided radiotherapy for localized prostate cancer.
Teunissen FR, Wortel RC, Wessels FJ, Claes A, van de Pol SMG, Rasing MJA, Meijer RP, van Melick HHE, de Boer JCJ, Verkooijen HM, van der Voort van Zyp JRN
Clinical and translational radiation oncology. 2022; 32(): 29-34

Evolution of Focal Therapy in Prostate Cancer: Past, Present, and Future.
Arcot R, Polascik TJ
The Urologic clinics of North America. 2022; 49(1): 129-152

New Technologies for Treatment of Benign Prostatic Hyperplasia.
Elterman D, Gao B, Lu S, Bhojani N, Zorn KC, Chughtai B
The Urologic clinics of North America. 2022; 49(1): 11-22

Synchronous early-stage breast cancer and axillary follicular lymphoma diagnosed by core needle biopsy: A case report.
Eto R, Nakamura R, Yamamoto N, Miyaki T, Hayama S, Sonoda I, Itami M, Tsujimura H, Hashimoto H, Otsuka M
Molecular and clinical oncology. 2022; 16(1): 3

Full-text options

Latest Statistics about COVID-19
• pubstat.org

Add your Article(s) to Indexes
• citeindex.org

Covid-19 Trends and Statistics
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMed® Information Services.

ScopeMed Web Sites